003850.KO Boryung Pharm
- Market cap
- KRW 696B
- P/E
- 5.7x
- P/B
- 0.76x
- ROE
- 14.6%
- Dividend yield
- 1.21%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 003850.KO undervalued?
Graham number003850.KO trades 56.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Boryung Pharm fundamental analysis
No fundamental analysis for Boryung Pharm yet.
Boryung Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Full company profileBoryung Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Boryung Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 409B | 423B | 460B | 524B | 562B | 627B | 760B | 860B | 1.02T | 1.02T | 1.07T |
| Gross Profit | 177B | 168B | 189B | 223B | 231B | 265B | 307B | 353B | 363B | 372B | 398B |
| Operating Income | 22.0B | 1.02B | 25.0B | 39.1B | 40.0B | 41.4B | 56.6B | 68.3B | 70.5B | 65.1B | 87.9B |
| EBITDA | - | 93.0B | 42.8B | 60.0B | 67.0B | 107B | 103B | 110B | 115B | 125B | 233B |
| Net Income | 5.61B | 56.7B | 20.3B | 32.2B | 26.9B | 43.0B | 41.9B | 40.2B | 69.6B | 64.3B | 131B |
| EPS | - | 1,190 | 431 | 683 | 584 | 651 | 636 | 610 | 829 | 761 | 1,550 |
| Balance Sheet | |||||||||||
| Total Assets | 398B | 403B | 450B | 508B | 648B | 829B | 892B | 916B | 1.16T | 1.39T | 1.53T |
| Total Liabilities | 203B | 153B | 194B | 225B | 308B | 354B | 376B | 366B | 380B | 542B | 636B |
| Shareholders' Equity | 195B | 250B | 256B | 283B | 340B | 474B | 516B | 549B | 785B | 846B | 895B |
| Cash & Short-term Investments | 26.3B | 16.4B | 7.62B | 4.52B | 25.5B | 151B | 16.1B | 16.5B | 187B | 228B | 50.0B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 9.36B | -24.6B | 38.9B | 47.0B | 44.7B | 60.2B | 27.8B | 42.2B | 80.6B | 133B | 107B |
| Capital Expenditure | 26.8B | 63.0B | 54.8B | 67.0B | 18.3B | 16.1B | 20.3B | 23.3B | 20.0B | 29.9B | 601B |
| Free Cash Flow | - | -91.3B | -18.2B | -21.8B | -11.9B | 850M | -95.2B | 18.9B | 60.5B | 103B | -494B |
| Ratios | |||||||||||
| ROE | 2.9% | 22.7% | 7.9% | 11.4% | 7.9% | 9.1% | 8.1% | 7.3% | 8.9% | 7.6% | 14.6% |
| ROA | 1.4% | 14.1% | 4.5% | 6.3% | 4.1% | 5.2% | 4.7% | 4.4% | 6.0% | 4.6% | 8.6% |
| Net Profit Margin | 1.4% | 13.4% | 4.4% | 6.1% | 4.8% | 6.9% | 5.5% | 4.7% | 6.8% | 6.3% | 12.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Boryung Pharm dividends
- Dividend yield
- 1.21%
- Forward dividend
- 160.00 KRW
- Payout ratio
- 13.1%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 8.40B | 99 | 13.1% |
| 2024 | KRW 6.77B | 81 | 9.7% |
| 2023 | KRW 6.59B | 100 | 16.4% |
| 2022 | KRW 6.59B | 100 | 15.7% |
| 2021 | KRW 4.51B | 68 | 10.5% |
| 2020 | KRW 4.20B | 91 | 15.7% |
| 2019 | KRW 2.52B | 53 | 7.8% |
| 2018 | KRW 6.80B | 144 | 33.5% |
| 2017 | KRW 1.62B | 34 | 2.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jul 16, 2021.
Who owns Boryung Pharm
- Insiders 65.54%
- Institutions 6.50%
- Public & others 27.96%
- Shares outstanding 81.7M
- Free float 28.3M
Boryung Pharm company profile
- Company name
- Boryung Pharm
- Ticker
- 003850.KO
- ISIN
- KR7003850005
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Boryeong Building, Seoul, South Korea, 03127
- Phone
- 82 2 708 8000
- Website
- boryung.co.kr
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, South Korea.
Boryung Pharm management
3- Mr. Jung-Gyun KimChairman & CEO · born 1985
- Daniel ChangChief Executive Officer of Pharma Biz
- Mr. Sung Jin KimChief Strategy Officer & Director · born 1987